In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to ...

French clinical-stage biotechnology and microbiome therapy company MaaT Pharma has seen success with its Phase III trial of MaaT013 meeting its primary endpoints, leading to a jump in the company ...

IFC Films, the studio behind “Late Night With the Devil” and “Memoir of a Snail,” has tapped Ayo Kepher-Maat as its new vice president of acquisitions and productions.

MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)LYON, France-- (BUSINESS WIRE)-- Regulatory News: These encouraging ...

Former Decal and Neon executive Ayo Kepher-Maat has joined the IFC Films in the new role of VP, acquisitions and productions.

MaaT Pharma will also present its ongoing Phase 2b trial (PHOEBUS) design for MaaT033 developed as an adjunctive therapy to enhance overall survival in allo-HSCT.

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago.

Strig Artist Management is bolstering its team, bringing on Christina Montojo as Manager and promoting Maat Bates from assistant to Coordinator.

Maat was crucial to human life and included ideas of truth, justice and moderation. If Maat was lost, the country could experience chaos - 'Isfet'.

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning the biotech to seek approval of the microbiome therapy in Europe in mid ...

LYON, France, May 12, 2025--MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS) ...